May 6, 2025 12:00PM
Jul 26, 2022 08:05AM
Jul 26, 2022 08:00AM
Jul 26, 2022 08:00AM
May 16, 2022 04:02PM
May 16, 2022 04:01PM
May 16, 2022 04:01PM AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
May 10, 2022 08:00AM
May 10, 2022 08:00AM
Feb 14, 2022 07:00AM
Feb 14, 2022 07:00AM
Feb 8, 2022 06:53PM
Feb 8, 2022 07:00AM
Feb 8, 2022 07:00AM AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia
Jan 11, 2022 08:00AM
Jan 11, 2022 08:00AM
Nov 12, 2021 08:00AM
Nov 10, 2021 04:18PM
Nov 9, 2021 07:00AM
Oct 14, 2021 05:00PM
Sep 28, 2021 08:00AM AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Sep 23, 2021 04:05PM
Jun 24, 2021 07:14AM
Jun 24, 2021 07:00AM
May 17, 2021 04:05PM
May 13, 2021 04:03PM
May 6, 2021 08:47AM
May 6, 2021 07:00AM AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
Mar 2, 2021 09:28AM
Mar 1, 2021 05:35PM
Feb 11, 2021 07:00AM
Nov 16, 2020 04:05PM
Nov 11, 2020 07:05AM
Nov 11, 2020 07:00AM
Sep 9, 2020 07:07AM Applied Genetic Technologies (AGTC) Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results
Sep 9, 2020 07:00AM
Sep 2, 2020 04:05PM
Aug 25, 2020 07:07AM
Aug 25, 2020 07:00AM
Aug 12, 2020 07:00AM
Jul 22, 2020 07:00AM
Jun 22, 2020 07:00AM AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
Jun 15, 2020 07:00AM
May 20, 2020 07:08AM
May 20, 2020 07:00AM
May 13, 2020 07:00AM
Feb 19, 2020 07:07AM
Feb 19, 2020 07:00AM
Jan 28, 2020 09:23AM Pre-Open Stock Movers 1/28: (DLPH) (XLRN) (ALKS) Higher (EROS) (BWA) (DDD) Lower (more...)
Jan 27, 2020 05:58PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All